HomeCompareNMTR vs VIG

NMTR vs VIG: Dividend Comparison 2026

NMTR yields 2770.08% · VIG yields 1.64%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NMTR wins by $212938372920.88M in total portfolio value
10 years
NMTR
NMTR
● Live price
2770.08%
Share price
$0.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$212938372920.91M
Annual income
$198,819,380,806,317,020.00
Full NMTR calculator →
VIG
Vanguard Dividend Appreciation ETF
● Live price
1.64%
Share price
$210.70
Annual div
$3.45
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.4K
Annual income
$179.15
Full VIG calculator →

Portfolio growth — NMTR vs VIG

📍 NMTR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNMTRVIG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NMTR + VIG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NMTR pays
VIG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NMTR
Annual income on $10K today (after 15% tax)
$235,457.06/yr
After 10yr DRIP, annual income (after tax)
$168,996,473,685,369,470.00/yr
VIG
Annual income on $10K today (after 15% tax)
$139.33/yr
After 10yr DRIP, annual income (after tax)
$152.28/yr
At 15% tax rate, NMTR beats the other by $168,996,473,685,369,300.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NMTR + VIG for your $10,000?

NMTR: 50%VIG: 50%
100% VIG50/50100% NMTR
Portfolio after 10yr
$106469186460.47M
Annual income
$99,409,690,403,158,610.00/yr
Blended yield
93.37%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NMTR buys
0
VIG buys
0
No recent congressional trades found for NMTR or VIG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNMTRVIG
Forward yield2770.08%1.64%
Annual dividend / share$2.00$3.45
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$212938372920.91M$32.4K
Annual income after 10y$198,819,380,806,317,020.00$179.15
Total dividends collected$211957883813.74M$1.7K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: NMTR vs VIG ($10,000, DRIP)

YearNMTR PortfolioNMTR Income/yrVIG PortfolioVIG Income/yrGap
1← crossover$287,708$277,008.31$11,304$163.92+$276.4KNMTR
2$7,756,221$7,448,373.17$12,759$166.33+$7.74MNMTR
3$195,960,759$187,661,602.67$14,382$168.52+$195.95MNMTR
4$4,640,768,087$4,431,090,074.46$16,192$170.52+$4640.75MNMTR
5$103,038,191,206$98,072,569,353.09$18,210$172.34+$103038.17MNMTR
6$2,145,287,049,877$2,035,036,185,286.86$20,460$173.98+$2145287.03MNMTR
7$41,893,666,105,695$39,598,208,962,326.13$22,968$175.48+$41893666.08MNMTR
8$767,520,675,750,287$722,694,453,017,193.00$25,763$176.83+$767520675.72MNMTR
9$13,195,319,733,262,706$12,374,072,610,209,900.00$28,878$178.05+$13195319733.23MNMTR
10$212,938,372,920,908,130$198,819,380,806,317,020.00$32,350$179.15+$212938372920.88MNMTR

NMTR vs VIG: Complete Analysis 2026

NMTRStock

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.

Full NMTR Calculator →

VIGETF

Seeks to track the performance of the S&P U.S. Dividend Growers Index.Passively managed, full-replication approach.Fund remains fully invested.Large-cap equity, emphasizing stocks with a record of growing their dividends year over year.Low expenses minimize net tracking error.With respect to 75% of its total assets, the fund may not: (1) purchase more than 10% of the outstanding voting securities of any one issuer or (2) purchase securities of any issuer if, as a result, more than 5% of the fund’s total assets would be invested in that issuer’s securities; except as may be necessary to approximate the composition of its target index. This limitation does not apply to obligations of the U.S. government or its agencies or instrumentalities.

Full VIG Calculator →
📬

Get this NMTR vs VIG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NMTR vs SCHDNMTR vs JEPINMTR vs ONMTR vs KONMTR vs MAINNMTR vs DGRONMTR vs NOBLNMTR vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.